A Phase 2 interventional study of CardiolRx in Acute Myocarditis, sponsored by Cardiol Therapeutics Inc.. Completed at 37 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Cardiol Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo.
CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC\<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imaging (CMR), ECG monitoring, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as physical exams and laboratory tests.
The primary and secondary outcome parameters are measured by CMR. Additional outcomes include clinical endpoints and changes in inflammatory and biomarkers.
Rationale:
Myocarditis is an acute inflammatory condition of the myocardium. Presentation of the disease may be fulminant and necessitate cardiac support, or even result in sudden cardiac death; milder cases are usually self-limiting but may progress to dilated cardiomyopathy with eventual end-stage heart failure. Other than treatments for associated heart failure there are no specific indicated treatments for myocarditis. CardiolRxTM (cannabidiol [CBD] solution), which is known to have anti-inflammatory properties, is being investigated to treat the underlying inflammatory process and thereby favorably modify acute myocarditis. The primary endpoints of the trial are cardiac magnetic resonance measures of left ventricular systolic function (ejection fraction and longitudinal strain) and myocardial edema (extra cellular volume) which have been shown to predict long term prognosis of patients with acute myocarditis.
Multi-center, double-blind, randomized, placebo-controlled, parallel group design. 1:1 randomization; treatment will be stratified within sites.
Patients diagnosed with acute myocarditis by a biopsy or a CMR will be screened within 10 days of the diagnostic CMR. Informed consent will be obtained at this point. For patients who have been diagnosed using an EMB, a CMR needs to be performed as well, which will be included in the informed consent form (ICF).Eligible patients will then be randomized within 10 days from the CMR assessment.
Baseline assessments include the following: Clinical assessment, including vital signs, ECG, 24-hr Holter, chest x-ray; Hematology and blood chemistry, NYHA classification, C SSRS and KCCQ. Frozen plasma will be retained for central analysis of hs-troponin, NT-proBNP and inflammatory markers.
Study treatment needs to be taken with food and will be initiated in the evening of Day 1, after all baseline assessments have been completed and the patient has been randomized.
Oral administration is as follows:
Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14):
5 mg/kg of body weight b.i.d. CardiolRxTM or placebo
7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo • Week 4 to end of treatment period (p.m. dose of Day 21 to
a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo
If the next higher dose after each study drug increase is not tolerated, the dose will be reduced to the previous tolerated dose.
Every week (before the next dose increase) the patient will be re-evaluated. This includes ECG monitoring at approximately 5 hours post-morning dose (time of Tmax) to surveil for deleterious effects on ECG intervals (particularly the QTc interval) and rhythm. Drug titration will be dependent on investigator or designate interrogation of the ECGs and the absence of new, clinically significant abnormalities on those ECGs.
Vital signs, concurrent medication and Adverse Events (AEs), including Serious Adverse Events (SAEs) will be recorded, blood chemistry including liver function tests, hematology as well as INR assessments will be carried out.
Final efficacy assessments (including a second CMR) will take place after 12 weeks of study treatment. A final safety assessment will take place after 13 weeks, 1 week after completion of study treatment.
174 studies on the registry are indexed under Myocarditis; 75 are open to participants now.
This study's enrollment of 109 is above the median of 80 across 53 interventional studies indexed under Myocarditis.
Browse Myocarditis studies →Cardiol Therapeutics Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with acute myocarditis including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo * Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo * Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo * Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo
Drug: CardiolRx
* Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo * Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo * Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo * Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo
Drug: CardiolRx
Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
Also known as: Cannabidiol
Extracellular Volume (ECV)
Change of ECV from baseline at 12 weeks, measured by cardiac Cardiac MRI. ECV is measuring the degree of edema and fibrosis. The unit of measure was percentage. It was the percentage of myocardial tissue that is extracellular space (i.e. fraction of the myocardium occupied by extracellular matrix and interstitial fluid).
Time frame: 12 weeks post randomization
Global Longitudinal Strain (GLS)
The outcome was the change in GLS from baseline at 12 weeks, measured by cardiac Cardiac MRI. GLS is a predictor of cardiac function. The unit of measure is percentage. It is the percent change in myocardial length relative to its original (end-diastolic) length along the long axis. Longitudinal strain during systole is usually negative, because the ventricle shortens; normal peak GLS in healthy adults is around -20% (i.e., 20% shortening relative to original length)
Time frame: 12 weeks post randomization
Change in Left-ventricular Ejection Fraction (LVEF) From Baseline at 12 Weeks
Left-ventricular ejection fraction (LVEF) as measured by Cardiac MRI at 12 weeks. LVEF is a measure of cardiac function. The unit of measure is percentage. It is the percent of end-diastolic blood volume in the left ventricle that is ejected with each systolic contraction. Mathematically, LVEF = (stroke volume/end-diastolic volume) x 100.
Time frame: 12 weeks post randomization
Change in Left-ventricular Mass From Baseline at 12 Weeks
Left-ventricular mass at week 12, measured with cardiac MRI. Unit of measure is grams (g) of myocardium. The mass of left-ventricular myocardial tissue was calculated from lCMR using geometric assumptions (e.g., Devereux/ASE cube formula) and myocardial density.
Time frame: From baseline to 12 weeks of treatment
166 patients signed informed consent between July 28, 2022, and October 31,2024, in 29 centers in Brazil; France; Israel and the United States. There were 57 screening failures and 109 patients were randomized to either CardiolRx™ (N=56) or Placebo (N=53). All randomized patients started the IMP and completed the study as planned - no patient withdrew prematurely from follow-up. In total, 11 patients discontinued the IMP before the Week 12 visit, 6 on CardiolRx and 5 on placebo.
| Milestone | CardiolRx | Placebo |
|---|---|---|
| Started | 56 | 53 |
| Completed | 56 | 53 |
| Not completed | 0 | 0 |
Change of ECV from baseline at 12 weeks, measured by cardiac Cardiac MRI. ECV is measuring the degree of edema and fibrosis. The unit of measure was percentage. It was the percentage of myocardial tissue that is extracellular space (i.e. fraction of the myocardium occupied by extracellular matrix and interstitial fluid).
| percentage of tissue volume outside cell | CardiolRx | Placebo |
|---|---|---|
| Extracellular Volume (ECV) | -1.88 ± 3.25 | -1.60 ± 4.57 |
The outcome was the change in GLS from baseline at 12 weeks, measured by cardiac Cardiac MRI. GLS is a predictor of cardiac function. The unit of measure is percentage. It is the percent change in myocardial length relative to its original (end-diastolic) length along the long axis. Longitudinal strain during systole is usually negative, because the ventricle shortens; normal peak GLS in healthy adults is around -20% (i.e., 20% shortening relative to original length)
| % of change in ventricle length | CardiolRx | Placebo |
|---|---|---|
| Global Longitudinal Strain (GLS) | -0.68 ± 3.6 | -0.62 ± 3.68 |
Left-ventricular ejection fraction (LVEF) as measured by Cardiac MRI at 12 weeks. LVEF is a measure of cardiac function. The unit of measure is percentage. It is the percent of end-diastolic blood volume in the left ventricle that is ejected with each systolic contraction. Mathematically, LVEF = (stroke volume/end-diastolic volume) x 100.
| percentage | CardiolRx | Placebo |
|---|---|---|
| Change in Left-ventricular Ejection Fraction (LVEF) From Baseline at 12 Weeks | 0.65 ± 8.38 | 1.75 ± 9.05 |
Left-ventricular mass at week 12, measured with cardiac MRI. Unit of measure is grams (g) of myocardium. The mass of left-ventricular myocardial tissue was calculated from lCMR using geometric assumptions (e.g., Devereux/ASE cube formula) and myocardial density.
| gram | CardiolRx | Placebo |
|---|---|---|
| Change in Left-ventricular Mass From Baseline at 12 Weeks | -11.11 ± 15.32 | -2.83 ± 23.39 |
The total Extracellular Volume (ECV) was calculated in mL using the following formula:Total ECV volume (mL) = ܸECV fraction (%) x LV mass (g)/ 1.05 where 1.05 = the specificgravity of myocardium in g/mL. It is the absolute extracellular volume of the tissue or body compartment, reported as physical volume instead of fraction or percent.
| mL | CardiolRx | Placebo |
|---|---|---|
| Change in Extracellular Volume (ECV) in ml From Baseline at 12 Weeks | -5.96 ± 7.35 | -2.73 ± 9.48 |
Collected over 16 weeks in France and 13 weeks for rest of the world (Brazil, Israel and US). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | 0/56 (0%) | 6/56 (10.7%) | 42/56 (75%) |
| Placebo | 0/53 (0%) | 3/53 (5.7%) | 35/53 (66%) |
| Event | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo |
|---|---|---|
| PalpitationCardiac disorders | 0/56 | 1/53 |
| Alanine aminotransferase increasedInvestigations | 1/56 | 1/53 |
| Aspartate aminotransferase increasedInvestigations | 0/56 | 1/53 |
| HypocalcemiaMetabolism and nutrition disorders | 0/56 | 1/53 |
| MyocarditisCardiac disorders | 1/56 | 0/53 |
| Ventricular TachycardiaCardiac disorders | 1/56 | 0/53 |
| GastritisGastrointestinal disorders | 1/56 | 0/53 |
| Chest painGeneral disorders | 1/56 | 0/53 |
| Transaminases increasedInvestigations | 1/56 | 0/53 |
| TremorNervous system disorders | 1/56 | 0/53 |
| Event | Cannabidiol, Pharmaceutically Produced With < 5 Ppm THC | Placebo |
|---|---|---|
| DiarrheaGastrointestinal disorders | 18/56 | 11/53 |
| Chest painGeneral disorders | 9/56 | 4/53 |
| AstheniaGeneral disorders | 1/56 | 7/53 |
| NauseaGastrointestinal disorders | 5/56 | 2/53 |
| Alanine aminotransferase increasedInvestigations | 5/56 | 3/53 |
| PalpitationsCardiac disorders | 1/56 | 4/53 |
| NasopharyngitisInfections and infestations | 0/56 | 3/53 |
| RashSkin and subcutaneous tissue disorders | 3/56 | 1/53 |
modified ITT analysis population
| Age, Continuous(years) | CardiolRx | Placebo | Total |
|---|---|---|---|
| Mean | 35.8 ± 15.35 | 39.6 ± 15.47 | 37.7 ± 15.45 |
| Sex: Female, Male(Participants) | CardiolRx | Placebo | Total |
|---|---|---|---|
| Female | 10 | 9 | 19 |
| Male | 39 | 41 | 80 |
| Race (NIH/OMB)(Participants) | CardiolRx | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 7 |
| White | 38 | 41 | 79 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 6 | 5 | 11 |
| Region of Enrollment(participants) | CardiolRx | Placebo | Total |
|---|---|---|---|
| United States | 4 | 4 | 8 |
| Brazil | 22 | 28 | 50 |
| Israel | 7 | 7 | 14 |
| France | 16 | 11 | 27 |
| Global longitudinal strain (GLS)(%) | CardiolRx | Placebo | Total |
|---|---|---|---|
| Mean | -15.35 ± 3.10 | -15.34 ± 4.06 | -15.35 ± 3.60 |
| Extracellular volume (ECV)(%) | CardiolRx | Placebo | Total |
|---|---|---|---|
| Mean | 29.74 ± 4.47 | 30.83 ± 4.31 | 30.29 ± 4.40 |
| Left-ventricular ejection fraction (LVEF)(%) | CardiolRx | Placebo | Total |
|---|---|---|---|
| Mean | 61.90 ± 8.88 | 59.35 ± 10.79 | 60.61 ± 9.93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Jan 2025, 30 months.
Results were first posted in Jun 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Cardiol Therapeutics Inc.